Citation only
via OpenAlex
Development and validation of a Medicare health outcomes survey (MHOS) frailty index in multiple myeloma (MM).
Mark Aaron Fiala, Emily Jean Guerard, Mark A. Schroeder, Keith E Stockerl-Goldstein, Ravi Vij, Tanya Marya Wildes
Journal of Clinical Oncology · 2017 · ▲ 4 citations
Abstract
e21519 Background: Increasing age is associated with poorer outcomes in MM. However, biological aging (BA) is heterogeneous and does not correlate perfectly with chronological age (CA). A recently developed frailty of CA, functional status, and comorbidities is more predictive of toxicity, progression-free and overall survival (OS) than CA alone (Palumbo et al Blood 2015). We sought to apply the Rockwood Accumulation of Deficits approach to develop and validate a frailty index (FI) for older adults with MM. Methods: MHOS, a random survey of HRQOL (health related quality of life) in Medicare Advantage HMO enrollees, data were obtained from 1,747,042 non-cancer patients (pts) and 340 with newly diagnosed MM 1997-2011 from the SEER-MHOS linked dataset. In creating the FI, we considered only variables available throughout all 4 survey versions used since its initiation in 1998. We identified 34 variables including items related to function/mobility, comorbidities, and mental health. The FI was calculated as the number of deficits present, divided by the number total number of possible deficits, with possible scores ranging from 0 to 1 and higher values indicating more frail. Missing data points were excluded from the FI calculation. Cox regression analysis was performed to determine the association of the FI with OS, controlling for CA, gender, and race. The FI was first derived in the non-cancer cohort then applied in the MM cohort. Results: The median age was 72 for non-cancer pts and 75 for pts with MM; the median FI was 0.308 and 0.368, respectively. Among non-cancer pts, each 10% increase in FI (~3-4 more deficits) was associated with a 35% increased risk for death (aHR 1.352, 95% CI 1.350-1.354, p < 0.001); among pts with MM it was associated with a 15% increased risk (aHR 1.147, 1.065-1.236, p < 0 .001). Median OS for pts with MM in the lowest tertile of FI was 48 months (95% CI 42-56) compared to 23 months (17-33) for the highest tertile. Conclusions: Here we present a MHOS-based FI. The FI was more prognostic among non-cancer pts than among pts with MM, presumably because stage and tumor characteristics also contribute to OS in MM pts. Further exploration of the MHOS-FI in MM and other cancers is warranted.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1200/jco.2017.35.15_suppl.e21519
- Canonical
- link ↗
- Fetched
- 2026-10-14 MST
Cite this
APA
Fiala, M.A., Guerard, E.J., Schroeder, M.A., Stockerl-Goldstein, K.E., Vij, R., & Wildes, T.M. (2017). Development and validation of a Medicare health outcomes survey (MHOS) frailty index in multiple myeloma (MM). <em>Journal of Clinical Oncology</em>. https://doi.org/10.1200/jco.2017.35.15_suppl.e21519
Vancouver
Fiala MA, Guerard EJ, Schroeder MA, Stockerl-Goldstein KE, Vij R, Wildes TM. Development and validation of a Medicare health outcomes survey (MHOS) frailty index in multiple myeloma (MM). Journal of Clinical Oncology. 2017. doi:10.1200/jco.2017.35.15_suppl.e21519.
BibTeX
@article{mark2017Develo,
title = {Development and validation of a Medicare health outcomes survey (MHOS) frailty index in multiple myeloma (MM).},
author = {Mark Aaron Fiala and Emily Jean Guerard and Mark A. Schroeder and Keith E Stockerl-Goldstein and Ravi Vij and Tanya Marya Wildes},
journal = {Journal of Clinical Oncology},
year = {2017},
doi = {10.1200/jco.2017.35.15_suppl.e21519},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
The Journals of Gerontology Series A 2005
Citation only
Frailty Index as a Measure of Biological Age in a Chinese Population
BMC Geriatrics 2008
Open access · CC-BY
A standard procedure for creating a frailty index
Vision (Basel, Switzerland) 2026
Open access · OA
Outcomes of Intravitreal Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration in Kazakhstan.
Haematologica 2017
Open access · OA
A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients
Respirology 2016
Citation only
Frailty is common and strongly associated with dyspnoea severity in fibrotic interstitial lung disease
BMC Cancer 2018
Open access · CC-BY